Successful ustekinumab treatment in a patient with psoriasis and subacute cutaneous lupus erythematosus

Mazgaj, Magdalena; Picard‐Dahan, C.; Deschamps, Lydia; Marinho, E.; Estève, É.; Descamps, V.

doi:10.1111/ijd.14773

Cited by 7 publications

(9 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… PDE-4 Inhibitor De Souza (2012) 19 Prospective Apremilast 30 mg BID CLASI showed a significant (P<0.05) decrease after 85 days of treatment in 8 patients with active DLE. Biologic Therapy Mazgaj (2020) 20 Case report Ustekinumab 45 mg SC at weeks 0, 4, then every 12 weeks A 65-year-old patient with SCLE and psoriasis. The patient reported only partial remission of psoriatic plaques with ustekinumab 45 mg, hence the dose was increased to 90 mg every 8 weeks, leading to long-term resolution of both psoriasis and CLE with excellent tolerance.…”

Section: Resultsmentioning

confidence: 99%

“…Partial or complete remission of cutaneous eruptions, erythema, and ulcerations was observed in all cases. 20 , 21 In one RCT, van Vollenhoven et al showed that ustekinumab 6 mg/kg IV infusion followed by a 90 mg SC dose every eight weeks led to significant improvement compared to placebo. 22 A prolonged Phase II study was conducted over two years with 46 patients, which showed further improvement in CLASI without significant adverse effects.…”

Section: Resultsmentioning

confidence: 99%

“…19 Additionally, the use of biologic therapies – including ustekinumab, tildrakizumab, anifrolumab, and BIIB059 – were effective in reducing cutaneous manifestations of CLE. 20–27 However, the anti-IFNγ antibody AMG 811 was not found to be effective in the treatment of DLE when compared to placebo. 28 …”

Section: Discussionmentioning

confidence: 99%

“…19 Additionally, the use of biologic therapies -including ustekinumab, tildrakizumab, anifrolumab, and BIIB059 -were effective in reducing cutaneous manifestations of CLE. [20][21][22][23][24][25][26][27] However, the anti-IFNγ antibody AMG 811 was not found to be effective in the treatment of DLE when compared to placebo. 28 Research has shown that the pathophysiology of CLE lesions is, in part, attributable to aberrant type I IFN production [32141953].…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Advancements in the Treatment of Cutaneous Lupus Erythematosus and Dermatomyositis: A Review of the Literature

Elhage¹,

Zhao²,

Nakamura³

2022

CCID

View full text Add to dashboard Cite

Background Cutaneous lupus erythematosus (CLE) and dermatomyositis (DM) are autoimmune diseases that present with a wide variety of cutaneous manifestations. In both cases, first-line therapy includes topical corticosteroids. Patients may present with more widespread disease requiring systemic treatments, including corticosteroids, traditional immunosuppressants, or antimalarials. Due to their complex nature, both CLE and DM remain difficult to treat and continue to cause significant distress to patients. Objective To summarize the most recent literature on the safety and efficacy of novel treatment modalities for CLE and DM. Methods A literature search was conducted on PubMed using search terms “(dermatomyositis) AND (treatment)” and “(cutaneous lupus) AND (treatment)”. Additional search terms included specific names of biologic agents, phosphodiesterase inhibitors (apremilast), and JAK inhibitors. Results JAK inhibitors, PDE-4 inhibitors, and biologics have shown promise in reducing cutaneous symptoms of both CLE and DM, including reduction in SLE Disease Activity Index 2000 (SLEDAI-2K), Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI), British Isles Lupus Assessment Group (BILAG), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), and Disease Activity Score (DAS). Conclusion While there have been recent advancements in the treatment for CLE and DM, further research and clinical trials are required to better elucidate which therapy is best for individual patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Advancements in the Treatment of Cutaneous Lupus Erythematosus and Dermatomyositis: A Review of the Literature

Elhage¹,

Zhao²,

Nakamura³

2022

CCID

View full text Add to dashboard Cite

show abstract

“…17 Recently, Ustekinumab, an inhibitor of Th17 cell differentiation was used to successfully treat a patient with psoriasis and SCLE. 18 Also, a clinical trial of Secukinumab, an inhibitor of IL-17A to treat DLE is to be conducted (NCT03866317). 19 The growing evidences suggest IL-17A blockades are a potential treatment for CLE.…”

Section: Discussionmentioning

confidence: 99%

Characterization of autoantibodies and cytokines related to cutaneous lupus erythematosus

Zhang

Yin

et al. 2020

Lupus

View full text Add to dashboard Cite

Objective To investigate the profiles of anti-RPLP0, anti-galectin3 antibodies, interferon-α (IFN-α), interferon-λ1(IFN-λ1) and interleukin-17A/F(IL-17A/F) in the subtypes of cutaneous lupus erythematosus (CLE) including acute CLE (ACLE), subacute CLE (SCLE) and discoid lupus erythematosus (DLE). Methods Serum levels of autoantibodies and cytokines were determined by enzyme-linked immunoabsorbent assay (ELISA). Lupus lesions were evaluated by cutaneous lupus erythematosus disease area and severity index (CLASI). Results Serum anti-RPLP0, anti-galectin3 antibodies and IFN-λ1 were higher in systemic lupus erythematosus (SLE) patients with skin lesions than those without skin lesions, compared to healthy controls. IFN-α, IL-17A and IL-17F was elevated in all patients regardless of skin lesions. The two antibodies, IFN-α and IL-17A were positively correlated with the CLASI score in all patients with CLE. In addition, serum IL-17A was positively correlated to the CLASI score of ACLE, SCLE and DLE, while anti-RPLP0 and anti-galectin3 antibodies were only correlated to the score of SCLE and IL-17F to DLE. Conclusion Serum anti-RPLP0, anti-galectin3 antibodies, IFN-α, IFN-λ1 and IL-17A/F are associated with the occurrence of lupus skin lesions regardless of the systemic complications, whereas the profiles of these inflammatory mediators vary with the subtypes of lupus skin lesions.

show abstract

Hydroxychloroquine/thalidomide

2020

Reactions Weekly

View full text Add to dashboard Cite

Successful ustekinumab treatment in a patient with psoriasis and subacute cutaneous lupus erythematosus

Cited by 7 publications

References 7 publications

Advancements in the Treatment of Cutaneous Lupus Erythematosus and Dermatomyositis: A Review of the Literature

Advancements in the Treatment of Cutaneous Lupus Erythematosus and Dermatomyositis: A Review of the Literature

Characterization of autoantibodies and cytokines related to cutaneous lupus erythematosus

Hydroxychloroquine/thalidomide

Contact Info

Product

Resources

About